ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1113

Urinary Biomarkers and Joint Cognition-Gait Trajectories: Findings from the Health, Aging, and Body Composition (ABC) Study

Session Information

  • Geriatric Nephrology
    November 08, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Geriatric Nephrology

  • 1300 Geriatric Nephrology

Authors

  • Shrestha, Aman, University of Maryland Baltimore School of Medicine, Baltimore, Maryland, United States
  • Shardell, Michelle, University of Maryland Baltimore School of Medicine, Baltimore, Maryland, United States
  • Chen, Chixiang, University of Maryland Baltimore School of Medicine, Baltimore, Maryland, United States
  • Seliger, Stephen L., University of Maryland Baltimore School of Medicine, Baltimore, Maryland, United States
  • Ginsberg, Charles, University of California San Diego, La Jolla, California, United States
  • Miller, Lindsay M., University of California San Diego, La Jolla, California, United States
  • Cawthon, Peggy M., California Pacific Medical Center, San Francisco, California, United States
Background

Emerging urinary biomarkers can unlock new links between kidney tubular injury and cognitive-physical function.

Methods

Using the Health ABC Study, we examined baseline urinary biomarkers—uromodulin, alpha-1 microglobulin (α1M), amino-terminal propeptide of type-III procollagen (PIIINP), neutrophil gelatinase-associated lipocalin (NGAL), interlukin-18 (IL-18), and kidney injury molecule-1 (KIM-1)—and joint cognition-gait trajectories among baseline high-function older adults. IL-18 and KIM-1 were measured in n=1902 participants; uromodulin, α1M, PIIINP and NGAL were measured in a random subcohort (n=502). Group-based trajectory analysis of 20m usual gait speed and modified Mini-Mental State up to year 10 revealed three groups: high cognitive-physical function (Group 1), stable cognition/declining gait (Group 2), and rapid joint decline (Group 3).

Results

After adjusting for covariates in separate models (Model-1A), higher α1M (p=0.043) and KIM-1 (p=0.005) concentrations were related to worse trajectories (Table). Further adjustment for estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR) and c-reactive protein (CRP) (Model-1B) attenuated estimates; KIM-1 was not quite significant (p=0.059). In a fully adjusted model of all urinary markers (Model-2), only KIM-1 was significant (p=0.012), but the set of urinary biomarkers was jointly significant (p=0.022).

Conclusion

KIM-1 was robustly related to cognitive-gait decline, and may link kidney tubular injury with aging-related functional outcomes.

Table. Multinomial Regression
Biomarker (per-doubling at Year 1)Group (vs. 1)Model 1AModel 1BModel 2
NOR95%CIp-valueJoint p-valueNOR95%CIp-valueJoint p-valueNOR95%CIp-valueJoint p-value
Uromodulin (ng/mL)22940.860.62–1.200.380.122740.810.55–1.190.290.221950.660.37–1.180.160.077
31.160.78–1.730.471.090.69–1.170.7041.230.61–2.480.57
α1M (mg/dL)22051.460.85–2.520.170.0431981.400.77–2.570.270.390.550.24–1.280.160.38
32.141.17–3.930.0141.610.81–3.200.180.630.24–1.660.35
PIIINP (μg/L)22871.260.98–1.630.0710.0902691.260.96–1.640.0920.241.730.80–3.780.170.17
31.421.00–2.010.0511.180.83–1.680.362.500.95–6.580.064
NGAL (ng/mL)22940.940.83–1.060.310.342740.930.81–1.050.250.390.800.66–0.980.0270.060
31.030.89–1.190.691.010.85–1.180.950.960.74–1.230.73
IL-18 (pg/mL)214361.050.96–1.150.290.1413601.040.94–1.140.470.521.300.81–2.090.280.11
31.111.00–1.240.0481.070.95–1.200.250.800.46–1.400.44
KIM-1 (pg/mL)215291.131.03–1.250.0150.00514341.121.01–1.250.0440.0592.001.27–3.150.0030.012
31.211.08–1.360.0021.161.02–1.320.0251.811.01–3.250.046

Model-1A = Adjusted for sociodemographics. Model-1B = Additionally adjusted for CKD-EPI eGFR, log-2 UACR and log-2 serum CRP. Model-2 = Additionally adjusted for all other biomarkers. P Model-2 versus model without urinary markers, p=0.022.

Funding

  • Other NIH Support

Digital Object Identifier (DOI)